Precision BioSciences
Precision BioSciences is a clinical-stage biotechnology company developing in vivo gene editing therapies using its proprietary ARCUS platform. Its lead programs — PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy — target diseases lacking curative treatments, with revenue generated through licensing and milestone payments from partners.
- Company typePublic
- Founded2006
- HeadquartersDurham, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Precision BioSciences does
Precision BioSciences is a clinical-stage biotechnology company founded in 2006 and headquartered in Durham, North Carolina, developing in vivo gene editing therapies using its proprietary ARCUS genome editing platform. The company targets diseases with high unmet medical need where current treatments are inadequate or non-curative, focusing on chronic hepatitis B (affecting over 300 million people globally) and Duchenne muscular dystrophy (approximately 15,000 patients in the US). Precision also maintains a portfolio of earlier-stage programs including PBGENE-PMM for primary mitochondrial myopathy, PBGENE-ALS for amyotrophic lateral sclerosis, and PBGENE-PCSK9 for cardiovascular disease.
The ARCUS platform is built on the I-CreI homing endonuclease originally discovered in Chlamydomonas reinhardtii algae. Its technical differentiation rests on three properties: a single-component architecture (only the I-CreI-derived nuclease both recognizes and cuts DNA), a small footprint of approximately 1,500 base pairs that enables delivery via AAV and accommodates larger payloads, and a 3-prime overhang cut that supports homology-directed repair. The wholly owned clinical programs — PBGENE-HBV (ELIMINATE-B Phase 1, 16 patients dosed across five cohorts, 1-log cccDNA reduction with durable pgRNA loss) and PBGENE-DMD (FUNCTION-DMD Phase 1/2 initiated at Arkansas Children's Hospital, designed to address roughly 60% of DMD patients via exons 45-55 excision) — represent the core value drivers.
The business model is partner-centric and milestone-driven. Precision generates revenue through upfront payments, development and regulatory milestone payments, and royalties on net sales of licensed programs, rather than through direct product sales. Major agreements include exclusive global licenses to TG Therapeutics for azer-cel in autoimmune indications (up to $288M in potential milestones plus tiered royalties) and to Imugene for azer-cel in oncology ($198M in potential milestones), plus historical collaborations with Eli Lilly, Novartis, and iECURE. Q1 2026 revenue of $10.8 million (versus less than $0.1 million in Q1 2025) was driven primarily by a TG Therapeutics milestone and a legacy ARCUS agriculture collaboration. As of Q1 2026, the company held $125.8 million in cash, with management stating this funds operations through 2028 to support the planned PBGENE-HBV and PBGENE-DMD clinical milestones.
Precision BioSciences firmographics
Firmographics- Name
- Precision BioSciences
- Legal name
- Precision BioSciences, Inc.
- Website
- https://precisionbiosciences.com
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Precision BioSciences is a clinical-stage biotechnology company developing in vivo gene editing therapies using its proprietary ARCUS platform. Its lead programs — PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy — target diseases lacking curative treatments, with revenue generated through licensing and milestone payments from partners.
- Ownership category
- akta.pro rank
Precision BioSciences industry classification
Industry- Product category
- Gene Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo) (HLAAACAD)
- akta.pro secondary industries
- AAV Vector Gene Therapy Developers (HLAAACAA), Translational Medicine & Biomarkers (HLAIALAF)
Keywords
Where Precision BioSciences is headquartered
LocationHeadquarters
- HQ city
- Durham
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Precision BioSciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Licensing and Milestone Payments: Precision generates revenue through licensing agreements with partners like TG Therapeutics and Imugene. These agreements provide upfront payments, milestone payments upon achievement of clinical/regulatory/commercial events, and royalty payments on net sales. The TG Therapeutics deal includes up to $288M in potential milestone payments plus high-single-digit to low-double-digit royalties.
- Collaboration Revenue: Revenue from collaboration agreements including legacy ARCUS agriculture collaborations and research partnerships. Q1 2026 revenue of $10.8 million was driven by milestone revenue from TG Therapeutics license agreement and legacy ARCUS agriculture collaboration.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Precision BioSciences product offering
Product offeringCore offering
Precision BioSciences is a clinical-stage biopharmaceutical company developing in vivo gene editing therapies using its proprietary ARCUS genome editing platform. The company focuses on curative treatments for chronic hepatitis B, Duchenne muscular dystrophy, and other genetic diseases, with additional programs in oncology cell therapy through licensed assets including azer-cel.
Product overview
Precision BioSciences is a clinical-stage gene editing company developing in vivo gene editing therapies using its proprietary ARCUS genome editing platform. The company's portfolio centers on PBGENE-HBV (gene editing therapy for chronic hepatitis B) and PBGENE-DMD (gene editing therapy for Duchenne muscular dystrophy), both wholly owned clinical-stage programs. Additional programs include PBGENE-PMM for primary mitochondrial myopathy, PBGENE-ALS for ALS, and PBGENE-PCSK9 for cardiovascular disease. The company has out-licensed azercabtagene zapreleucel (azer-cel) to Imugene for cancer and to TG Therapeutics for autoimmune diseases. The ARCUS platform, based on I-CreI homing endonuclease technology, enables sequence-specific DNA insertion, removal, and repair in living cells.
Differentiator
Problem solved
Functional benefit
Brands
- ARCUS: Proprietary genome editing platform based on naturally occurring I-CreI enzyme for gene insertion, removal, and repair in living cells and tissues
- PBGENE-HBV
- PBGENE-DMD
Products and services
- PBGENE-HBV Investigational in vivo gene editing therapy for chronic hepatitis B virus (HBV) infection, designed to use ARCUS nucleases to inactivate cccDNA and integrated HBV DNA for a functional cure.
- PBGENE-DMD Investigational in vivo gene editing therapy for Duchenne muscular dystrophy (DMD), designed to use ARCUS to remove exons 45-55 of the dystrophin gene and restore dystrophin protein expression.
- Azercabtagene Zapreleucel (azer-cel) Allogeneic CAR T-cell therapy candidate for CD19-positive B-cell malignancies, developed using ARCUS gene editing and out-licensed to Imugene and TG Therapeutics.
- PBGENE-PCSK9 Investigational in vivo gene editing therapy targeting the PCSK9 gene to lower LDL cholesterol levels for cardiovascular disease, licensed to iECURE.
Quantifiable outcome
- 1-log (10-fold) reduction in cccDNA transcripts after two doses at 0.4 mg/kg in chronic hepatitis B patients
- +5 more outcomes
Companies that use Precision BioSciences
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Precision BioSciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Precision BioSciences partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered concluded, core, significant and minor.
- Prevail TherapeuticsconcludedPreviously collaborated on gene editing programs. Programs returned to Precision BioSciences and collaboration concluded in April 2024.
- TG TherapeuticscoreExclusive global license agreement for azer-cel (azercabtagene zapreleucel) for non-cancer indications including autoimmune diseases. Precision received $17.5M upfront (mix of cash and equity) with potential for up to $288M in milestone payments and high-single-digit to low-double-digit royalties on net sales. TG Therapeutics advancing azer-cel in multiple sclerosis Phase 1 trial.
- ImugenecoreExclusive global license to azer-cel for cancer indications. $29M upfront and potential near-term payments, $198M potential milestone payments, option to nominate up to three research programs each with $145M potential milestones and tiered royalties. Imugene assuming ongoing clinical execution for azer-cel in large B-cell lymphoma.
- NovartissignificantIn vivo gene editing collaboration to develop potentially curative treatment for disorders including sickle cell disease. Novartis collaboration announced June 2022.
- iECUREcoreLicense and collaboration agreement for ARCUS gene insertion programs. iECURE advancing ECUR-506 for OTC deficiency using licensed ARCUS nuclease technology. Precision holds equity stake in iECURE plus milestone payments and royalties. ECUR-506 received FDA Fast Track designation, RMAT designation, and was selected for FDA CDRP Program.
- University of PennsylvaniaminorResearch, collaboration, and license agreement with University of Pennsylvania for preclinical development of gene editing products involving delivery of an ARCUS nuclease. Collaboration includes work on PCSK9-directed ARCUS nuclease.
- SpringWorks TherapeuticsminorClinical collaboration to evaluate PBCAR269A in combination with nirogacestat in patients with relapsed or refractory multiple myeloma. SpringWorks providing nirogacestat while Precision provides PBCAR269A.
- Eli Lilly and CompanysignificantIn vivo gene editing collaboration and license agreement for developing gene editing therapies. Precision granted rights to apply ARCUS technology in target indication areas. Transaction closed January 2021.
Scale indicators13 records
Recent moves7 records
Expansion highlights6 records
Precision BioSciences competitors and assessment
Company assessmentDirect peers
- Intellia Therapeutics: Clinical-stage in vivo gene editing company using CRISPR/Cas9 platform; advancing programs in HAE, ATTR, and other indications. Most direct competitor given both companies are pursuing in vivo gene editing with proprietary platforms and clinical-stage assets.
- CRISPR Therapeutics: Developer of Cas9-based gene editing therapies including CASGEVY (approved sickle cell/beta-thalassemia). Competes with Precision in gene editing modality and shares target disease areas including hemoglobinopathies and rare genetic disorders.
- Editas Medicine: Clinical-stage CRISPR-based gene editing company developing in vivo and ex vivo therapies. Directly competes with Precision's ARCUS platform in gene editing space, with overlapping focus on rare genetic diseases.
- Beam Therapeutics: Clinical-stage base editing company developing precise gene editing therapies. Competes with Precision in next-generation gene editing technology and shares focus on in vivo editing applications.
- Verve Therapeutics: Clinical-stage in vivo gene editing company focused on cardiovascular disease, including PCSK9 editing program. Direct competitor to Precision in in vivo gene editing for cardiovascular indications.
- Sangamo Therapeutics: Clinical-stage gene editing company using zinc finger nuclease platform. Historical gene editing competitor with clinical assets in rare genetic diseases; comparable modality to ARCUS as engineered nuclease-based editing platform.
- Sarepta Therapeutics: Commercial-stage DMD-focused company with approved therapies including ELEVIDYS gene therapy. Most direct competitor to Precision's PBGENE-DMD program in Duchenne muscular dystrophy space.
- Vir Biotechnology: Clinical-stage company developing functional cure therapies for chronic hepatitis B. Direct competitor to Precision's PBGENE-HBV program in chronic HBV treatment.
Emerging players
- Solid Biosciences: Clinical-stage gene therapy company focused on DMD with AAV-based approaches. Emerging competitor in DMD space targeting similar patient population as Precision's PBGENE-DMD.
- Generation Bio: Clinical-stage genetic medicine company developing non-viral gene therapy using LNP delivery. Emerging player in in vivo gene editing/delivery space, with overlapping interest in liver-targeted therapies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Precision BioSciences social profiles
Digital presencePrecision BioSciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Precision BioSciences leadership team
Management profileNumber of profiles
Profiles18 records
Precision BioSciences subsidiaries and ownership
Company hierarchySubsidiaries1 record
Precision BioSciences funding detail
Funding detailFunding overview
Funding rounds8 records
Investors40 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Precision BioSciences M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Precision BioSciences
What does Precision BioSciences do?
Precision BioSciences is a clinical-stage biopharmaceutical company developing in vivo gene editing therapies using its proprietary ARCUS genome editing platform. The company focuses on curative treatments for chronic hepatitis B, Duchenne muscular dystrophy, and other genetic diseases, with additional programs in oncology cell therapy through licensed assets including azer-cel.
Is Precision BioSciences a public or private company?
Precision BioSciences is a public company. It is classified as public and is currently operating.
When was Precision BioSciences founded?
Precision BioSciences was founded in 2006. It employs 51 to 100 people.
Where is Precision BioSciences based?
Precision BioSciences is headquartered in Durham, United States, in the North America region.
How does Precision BioSciences make money?
Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are collaboration Revenue.
Who are Precision BioSciences's main competitors?
Direct peers on record are Intellia Therapeutics, CRISPR Therapeutics, Editas Medicine, Beam Therapeutics, Verve Therapeutics, Sangamo Therapeutics, Sarepta Therapeutics and Vir Biotechnology. Emerging players are Solid Biosciences and Generation Bio.
Does Precision BioSciences have an API?
No public API is recorded for Precision BioSciences.
What industry is Precision BioSciences in?
Precision BioSciences's product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAD, Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo), with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 2834.